Q-Line Biotech was incorporated on November 10, 2010. The company develops, manufactures, and markets diagnostic reagents, kits, consumables, and point-of-care devices, while also supplying diagnostic and pathology equipment for healthcare providers. Its operations span clinical chemistry, haematology, immunodiagnostics, molecular diagnostics, and rapid testing solutions
| Bidding Dates |
|---|
| 21 May 2026 - 25 May 2026 |
| Subscription |
|---|
| 95.31x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹2,60,800 | 2 | 2 | 400 | 6.3 M | ₹326 - ₹343 | 67.51 % | ₹2038.5 M - ₹2144.8 M | RHP DOC |
Q-Line Biotech IPO SUBSCRIPTION STATUS
25 May '26Q-Line Biotech IPO overall subscription rate was 95.31 times the total available shares
Q-Line Biotech IPO retail subscription rate was 94.9 times in the retail segment
Q-Line Biotech IPO non-institutional investor subscription rate was 194.49 times in the non-institutional investor category
Q-Line Biotech IPO Qualified Institutional Bidder subscription rate was 65.85 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
25 May 2026 (Day 3) | 94.9x | 194.49x | 65.85x |
22 May 2026 (Day 2) | 13.18x | 21.21x | 2.76x |
21 May 2026 (Day 1) | 4.79x | 6.96x | 2.2x |
Q-Line Biotech FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| 9MFY26 | 232.4 | 38.7 | -33.1 | -61.7 | 27.6% |
| FY25 | 313.8 | 28.1 | -1.3 | -57.6 | 22.7% |
| FY24 | 203.6 | 34.4 | -24.2 | -72.3 | 18.5% |
| FY23 | 182.7 | 32.1 | 25.0 | -1.3 | 18.1% |
Q-Line Biotech IPO SUBSCRIPTION STATUS DETAILS
Q-Line Biotech had 6.3 M shares on offer
Q-Line Biotech IPO offer price was in the range ₹326 - ₹343
Q-Line Biotech IPO minimum Investment was ₹260800
Q-Line Biotech IPO issue size was ₹ 2038.5 M - ₹ 2144.8 M
Q-Line Biotech had a minimum lot size of 400 Shares per application
Q-Line Biotech NUMBER OF SHARES ON OFFER
Q-Line Biotech IPO IMPORTANT DATES
| Issue Open Date | 21 May 2026 |
| Issue close Date | 25 May 2026 |
| Allotment Date | 26 May 2026 |
| Refund Date | 27 May 2026 |
| Demat Account Credit Date | 27 May 2026 |
| Listing Date | 29 May 2026 |
| Listing on Exchange(s) | NSE |
| Q-Line Biotech Allotment Status | Exchange/ Registrar |
Q-Line Biotech IPO subscription opened on 21 May 2026, and closed on 25 May 2026
IPO allotment for Q-Line Biotech was finalized on Tuesday, 26 May 2026
IPO listing for Q-Line Biotech was on NSE on Friday, 29 May 2026
Q-Line Biotech IPO LISTING GAINS
| Issue Price (adjusted) | 343.0 |
| Listing Open Price | 452.0 |
| Listing Close Price | 474.6 |
| Listing Gain% | 31.8% |
| Current Gain% | 57.1% |
Q-Line Biotech Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q-Line Biotech Ltd. | 538.7 | 1256.7 | 22.6 | 0.2 | 3.6 | 22.6 | 10 | 347.4 | 7.7 | 55.7 | 98.1 | 23.9 | 98.1 |
| Poly Medicure Ltd. | 1693.8 | 17168.3 | 54.5 | -4.6 | 8.6 | 10.4 | 8.2 | 1995.3 | 13.4 | 322.1 | -4.8 | 31.1 | -11.9 |
| Medplus Health Services Ltd. | 700.2 | 8412.6 | 40 | 2.2 | 1.2 | 11.1 | 5.6 | 6963.8 | 12.6 | 219.6 | 46.1 | 17.5 | 18 |
| Laxmi Dental Ltd. | 216.1 | 1187.6 | 41 | -4.7 | 4.3 | 11.9 | 9.8 | 286.4 | 18.1 | 29 | -8.8 | 5.3 | -8.8 |
| Vasa Denticity Ltd. | 408.6 | 679.1 | 68.5 | -2.2 | 2.3 | 5.7 | 5 | 283.4 | 12.8 | 9.9 | -41.6 | 6 | -31.3 |
| Nureca Ltd. | 342.6 | 342.6 | 79 | 0 | 2.2 | 1.2 | 1.1 | 155.1 | 27 | 2.1 | 146.1 | 4.3 | 144666.7 |
Q-Line Biotech INFORMATION ON IPO ISSUE
About Q-Line Biotech
Q-Line Biotech was incorporated on November 10, 2010. The company develops, manufactures, and markets diagnostic reagents, kits, consumables, and point-of-care devices, while also supplying diagnostic and pathology equipment for healthcare providers. Its operations span clinical chemistry, haematology, immunodiagnostics, molecular diagnostics, and rapid testing solutions
Object of the Issue
- To meet working capital requirements
- Repayment of certain borrowing availed by the company
- General corporate purpose
Q-Line Biotech - PROMOTERS
| Name |
|---|
| Saurabh Garg |
| Amita Garg |
| Ajay Kumar Mahanty |
| Abhay Agrawal |
| Ayush Garg |
Q-Line Biotech - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Saurabh Garg | Chairman & Managing Director |
| Kuldeep Chowdhry | Whole Time Director |
| Ajay Kumar Mahanty | Whole Time Director |
| Yethadka Subraya Prabhakara | Whole Time Director |
| Abhay Agrawal | Non-Executive Director |
| Amita Garg | Non-Executive Director |
| Ayush Garg | Non-Executive Director |
| Abhishek Mishra | Independent Director |
| Pravir Kumar | Independent Director |
| Rohit Nandan | Independent Director |
| Jai Prakash Singh | Independent Director |
Q-Line Biotech Book Running Lead Manager
Hem Securities Limited
ib@hemsecurities.com
Share India Capital Services Private Limited
mb@shareindia.com
Q-Line Biotech Registrar to the issue
Purva Sharegistry (India) Private Limited
newissue@purvashare.com
Q-Line Biotech Strengths
Strong R&D
The company has established manufacturing capabilities supported by research and development, reverse engineering, and quality control. Its dedicated R&D team focuses on product innovation, process improvement, and efficient manufacturing
Diverse portfolio
The company offers a diversified range of in-vitro diagnostic (IVD) products, including reagents, diagnostic kits, devices, instruments, and consumables. Its broad portfolio helps cater to multiple healthcare and diagnostic needs
Wide network
The company has an extensive distribution and service network supported by sales personnel, service engineers, and distributors across multiple regions. This helps strengthen customer support, product availability, and market reach
Q-Line Biotech Risks
Agreement dependence
The company relies on agreements with European companies for manufacturing support and raw material supply. Failure to renew these agreements on favorable terms could disrupt operations and impact financial performance
Distributor reliance
The company generates a significant portion of sales through distributors, including a group entity. Loss of key distributors or reduced sales through these channels could adversely impact revenue and operations
Supplier concentration
The company depends on certain key suppliers for critical raw materials and machines. Any disruption in supplier relationships or delays in procurement could impact production and customer deliveries
IPO FAQs
The promoters of the company are Saurabh Garg, Amita Garg, Ajay Kumar Mahanty, Abhay Agrawal and Ayush Garg.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 326.0 - 343.0.
The IPO application opens on May 21, 2026 and closes on May 25, 2026.
The minimum lot size for the IPO is 800. The maximum lot size for the IPO is 800.
For all category investors, the minimum application amount for this IPO is Rs. 260,800.0, the maximum value for this IPO is Rs 274,400.0.
This IPO will be allotted on May 26, 2026.
The refund will be credited to your account on May 27, 2026.
The allotted shares will be credited to your demat on May 27, 2026.
Q-Line Biotech Ltd.’s shares listed on the stock exchanges on May 29, 2026.